BOSTON SCIENTIFIC CORP
Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.
CAPITALIZATION 12/31/25
| ($ millions) | Amount | % |
|---|---|---|
| Total debt | 11,436 | 32.1 |
| Stockholders' equity | 24,233 | 67.9 |
| Total capitalization | 35,669 | 100.0 |
1,449,229,526 shares outstanding at 30 July 2026 (cover page of the 10-Q filed 3 August 2026).
LONG-TERM DEBT 12/31/25
| ($ millions) | Amount |
|---|---|
| Long-term debt, noncurrent | 11,137 |
| Current maturities | 299 |
CAPITAL STOCK 12/31/25
| Common shares authorized | 2,000,000,000 |
| Common shares issued | 1,746,290,165 |
| Treasury shares | 263,289,848 |
| Par or stated value per share ($) | 0.01 |
| Preferred stock ($ millions) | 0 |
| Outstanding at 7/30/26 | 1,449,229,526 |
DIVIDENDS DECLARED/PAID
| Fiscal year | Per share $ | Payout % |
|---|---|---|
| 2025 | – | – |
| 2024 | – | – |
| 2023 | – | – |
| 2022 | – | – |
| 2021 | – | – |
HISTORY AND BUSINESS
HISTORY: Incorporated in Delaware.
BUSINESS: Classified by the SEC under Standard Industrial Classification 3841, Surgical & Medical Instruments & Apparatus. Large accelerated filer. Principal executive office: 300 Boston Scientific Way, Marlborough, MA 01752-1234. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.
CONSOLIDATED INCOME ACCOUNT, YEARS ENDED
| ($ millions) | 12/31/25 | 12/31/24 | 12/31/23 |
|---|---|---|---|
| Revenues | 20,074 | 16,747 | 14,240 |
| Cost of revenues | 6,221 | 5,257 | 4,345 |
| Gross profit | 13,854 | 11,490 | 9,896 |
| Research and development | 2,052 | 1,615 | 1,414 |
| Selling, general and administrative | 6,887 | 5,984 | 5,190 |
| Depreciation and amortization | 1,368 | 1,269 | 1,196 |
| Operating income | 3,613 | 2,603 | 2,343 |
| Interest expense | 349 | 305 | 265 |
| Income before income taxes | 3,385 | 2,282 | 1,985 |
| Income taxes | 493 | 436 | 393 |
| Net income | 2,892 | 1,846 | 1,592 |
| Earned per share, diluted ($) | 1.94 | 1.25 | 1.07 |
| Dividends per share ($) | – | – | – |
CONSOLIDATED BALANCE SHEET
| ($ millions) | 12/31/25 | 12/31/24 |
|---|---|---|
| Cash and equivalents | 1,965 | 414 |
| Inventories | 2,943 | 2,810 |
| Total current assets | 8,794 | 6,920 |
| Property, plant and equipment, net | 4,036 | 3,294 |
| Goodwill | 18,282 | 17,089 |
| Total assets | 43,673 | 39,395 |
| Total current liabilities | 5,439 | 6,399 |
| Long-term debt | 11,137 | 8,968 |
| Stockholders' equity | 24,233 | 21,770 |
| Total liabilities and equity | 43,673 | 39,395 |
TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)
| Fiscal year ended | Revenues | Oper. income | Net income | Net margin % | EPS diluted $ | Div. per share $ | Oper. cash flow | Capital expend. | Free cash flow | Total assets | Total liabilities | Total debt | Stockholders' equity | ROE % | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/31/25 | 20,074 | 3,613 | 2,898 | 14.4 | 1.94 | – | 4,534 | 876 | 3,658 | 43,673 | 19,201d | 11,436 | 24,233 | 12.0 | 0.47 |
| 12/31/24 | 16,747 | 2,603 | 1,853 | 11.1 | 1.25 | – | 3,435 | 790 | 2,645 | 39,395 | 17,392d | 10,746 | 21,770 | 8.5 | 0.49 |
| 12/31/23 | 14,240 | 2,343 | 1,570 | 11.0 | 1.07 | – | 2,503 | 711 | 1,792 | 35,136 | 15,606d | 9,102 | 19,282 | 8.1 | 0.47 |
| 12/31/22 | 12,682 | 1,649 | 642 | 5.1 | 0.45 | – | 1,526 | 588 | 938 | 32,469 | 14,896d | 8,935 | 17,573 | 3.7 | 0.51 |
| 12/31/21 | 11,888 | 1,199 | 985 | 8.3 | 0.69 | – | 1,870 | 554 | 1,316 | 32,229 | 15,607d | 9,065 | 16,622 | 5.9 | 0.55 |
| 12/31/20 | 9,913 | (80) | (115) | -1.2 | (0.08) | – | 1,508 | 376 | 1,132 | 30,777 | 15,451d | 9,143 | 15,326 | -0.8 | 0.60 |
| 12/31/19 | 10,735 | 1,518 | 4,700 | 43.8 | 3.33 | – | 1,836 | 461 | 1,375 | 30,565 | 16,688d | 10,008 | 13,877 | 33.9 | 0.72 |
| 12/31/18 | 9,823 | 1,506 | 1,671 | 17.0 | 1.19 | – | 310 | 316 | (6) | 20,999 | 12,273d | 7,056 | 8,726 | 19.1 | 0.81 |
| 12/31/17 | 9,048 | 1,285 | 104 | 1.1 | 0.08 | – | 1,426 | 319 | 1,107 | 19,042 | 12,030d | 3,815 | 7,012 | 1.5 | 0.54 |
| 12/31/16 | 9,076 | 447 | 347 | 3.8 | 0.25 | – | 1,182 | 376 | 806 | 18,096 | 11,363d | 5,420 | 6,733 | 5.2 | 0.80 |
Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.
REGISTRANT:
BOSTON SCIENTIFIC CORP
CIK 885725 · EIN 04-2695240
PRINCIPAL OFFICE:
300 Boston Scientific Way, Marlborough, MA 01752-1234
Tel.: 508-683-4000
INCORPORATED:
Delaware
INDUSTRY (SEC SIC CODE):
3841 · Surgical & Medical Instruments & Apparatus
FILER STATUS:
Large accelerated filer
LATEST ANNUAL REPORT:
10-K for period ended 12/31/25, filed 17 February 2026
Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/17/26) · 10-K FY2024 (filed 2/18/25) · 10-K FY2023 (filed 2/20/24) · 10-K FY2022 (filed 2/23/23) · 10-K FY2021 (filed 2/23/22) · 10-K FY2020 (filed 2/23/21) · 10-K FY2019 (filed 2/25/20) · 10-K FY2018 (filed 2/19/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.
Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.